This is a multicenter, open-label, study to investigate the safety and tolerability of RP1 for the treatment of advanced CSCC in up to 30 evaluable organ transplant recipients. RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and generate an anti-tumor immune response. Patients will be dosed with RP1 by direct or ultrasound guided intra-tumoral injection into superficial, subcutaneous or nodal tumors. Efficacy will be measured by measuring adverse events, and the percentage of subjects experiencing organ allograft rejection.
Cincinnati-based nonprofit GIVEHOPE and consulting firm BSI Engineering are celebrating a philanthropic partnership that has funded 13 pilot research projects at the University of Cincinnati Cancer Center. Together, GIVEHOPE and BSI have raised $800,000 to benefit pancreatic cancer research, education, prevention and awareness programs at the UC Cancer Center.